210 related articles for article (PubMed ID: 27524416)
1. mTOR promotes pituitary tumor development through activation of PTTG1.
Chen R; Duan J; Li L; Ma Q; Sun Q; Ma J; Li C; Zhou X; Chen H; Jing Y; Zhao S; Wu X; Zhang H
Oncogene; 2017 Feb; 36(7):979-988. PubMed ID: 27524416
[TBL] [Abstract][Full Text] [Related]
2. The PTTG1-targeting miRNAs miR-329, miR-300, miR-381, and miR-655 inhibit pituitary tumor cell tumorigenesis and are involved in a p53/PTTG1 regulation feedback loop.
Liang HQ; Wang RJ; Diao CF; Li JW; Su JL; Zhang S
Oncotarget; 2015 Oct; 6(30):29413-27. PubMed ID: 26320179
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms for growth factor-induced pituitary tumor transforming gene-1 expression in pituitary folliculostellate TtT/GF cells.
Vlotides G; Cruz-Soto M; Rubinek T; Eigler T; Auernhammer CJ; Melmed S
Mol Endocrinol; 2006 Dec; 20(12):3321-35. PubMed ID: 16959877
[TBL] [Abstract][Full Text] [Related]
4. Suppression of PTTG1 inhibits cell angiogenesis, migration and invasion in glioma cells.
Cui L; Ren T; Zhao H; Chen S; Zheng M; Gao X; Feng D; Yang L; Jin X; Zhuo R
Med Oncol; 2020 Jul; 37(8):73. PubMed ID: 32725378
[TBL] [Abstract][Full Text] [Related]
5. Pttg1/securin is required for the branching morphogenesis of the mammary gland and suppresses mammary tumorigenesis.
Hatcher RJ; Dong J; Liu S; Bian G; Contreras A; Wang T; Hilsenbeck SG; Li Y; Zhang P
Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1008-13. PubMed ID: 24395789
[TBL] [Abstract][Full Text] [Related]
6. Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expression.
Horwitz GA; Miklovsky I; Heaney AP; Ren SG; Melmed S
Mol Endocrinol; 2003 Apr; 17(4):600-9. PubMed ID: 12554778
[TBL] [Abstract][Full Text] [Related]
7. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development.
Wu K; Ding J; Chen C; Sun W; Ning BF; Wen W; Huang L; Han T; Yang W; Wang C; Li Z; Wu MC; Feng GS; Xie WF; Wang HY
Hepatology; 2012 Dec; 56(6):2255-67. PubMed ID: 22898879
[TBL] [Abstract][Full Text] [Related]
8. NFκB up-regulation of glucose transporter 3 is essential for hyperactive mammalian target of rapamycin-induced aerobic glycolysis and tumor growth.
Zha X; Hu Z; Ji S; Jin F; Jiang K; Li C; Zhao P; Tu Z; Chen X; Di L; Zhou H; Zhang H
Cancer Lett; 2015 Apr; 359(1):97-106. PubMed ID: 25578782
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological targeting of mammalian target of rapamycin inhibits ovarian granulosa cell tumor growth.
Rico C; Laguë MN; Lefèvre P; Tsoi M; Dodelet-Devillers A; Kumar V; Lapointe E; Paquet M; Nadeau MÈ; Boerboom D
Carcinogenesis; 2012 Nov; 33(11):2283-92. PubMed ID: 22871496
[TBL] [Abstract][Full Text] [Related]
10. Tsc1 deficiency-mediated mTOR hyperactivation in vascular endothelial cells causes angiogenesis defects and embryonic lethality.
Ma A; Wang L; Gao Y; Chang Z; Peng H; Zeng N; Gui YS; Tian X; Li X; Cai B; Zhang H; Xu KF
Hum Mol Genet; 2014 Feb; 23(3):693-705. PubMed ID: 24129405
[TBL] [Abstract][Full Text] [Related]
11. RNAi-mediated knockdown of pituitary tumor- transforming gene-1 (PTTG1) suppresses the proliferation and invasive potential of PC3 human prostate cancer cells.
Huang SQ; Liao QJ; Wang XW; Xin DQ; Chen SX; Wu QJ; Ye G
Braz J Med Biol Res; 2012 Nov; 45(11):995-1001. PubMed ID: 22872288
[TBL] [Abstract][Full Text] [Related]
12. Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma.
Diegel CR; Cho KR; El-Naggar AK; Williams BO; Lindvall C
Cancer Res; 2010 Nov; 70(22):9143-52. PubMed ID: 21062985
[TBL] [Abstract][Full Text] [Related]
13. Pancreas-specific activation of mTOR and loss of p53 induce tumors reminiscent of acinar cell carcinoma.
Kong B; Cheng T; Qian C; Wu W; Steiger K; Cao J; Schlitter AM; Regel I; Raulefs S; Friess H; Erkan M; Esposito I; Kleeff J; Michalski CW
Mol Cancer; 2015 Dec; 14():212. PubMed ID: 26683340
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
Dai C; Zhang B; Liu X; Ma S; Yang Y; Yao Y; Feng M; Bao X; Li G; Wang J; Guo K; Ma W; Xing B; Lian W; Xiao J; Cai F; Zhang H; Wang R
Endocrinology; 2013 Mar; 154(3):1247-59. PubMed ID: 23384836
[TBL] [Abstract][Full Text] [Related]
15. Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells.
Tulipano G; Faggi L; Cacciamali A; Spinello M; Cocchi D; Giustina A
J Neuroendocrinol; 2015 Jan; 27(1):20-32. PubMed ID: 25323047
[TBL] [Abstract][Full Text] [Related]
16. Overactive mTOR signaling leads to endometrial hyperplasia in aged women and mice.
Bajwa P; Nielsen S; Lombard JM; Rassam L; Nahar P; Rueda BR; Wilkinson JE; Miller RA; Tanwar PS
Oncotarget; 2017 Jan; 8(5):7265-7275. PubMed ID: 27980219
[TBL] [Abstract][Full Text] [Related]
17. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
Neshat MS; Mellinghoff IK; Tran C; Stiles B; Thomas G; Petersen R; Frost P; Gibbons JJ; Wu H; Sawyers CL
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10314-9. PubMed ID: 11504908
[TBL] [Abstract][Full Text] [Related]
18. Expression of the mTOR pathway regulators in human pituitary adenomas indicates the clinical course.
Jia W; Sanders AJ; Jia G; Liu X; Lu R; Jiang WG
Anticancer Res; 2013 Aug; 33(8):3123-31. PubMed ID: 23898069
[TBL] [Abstract][Full Text] [Related]
19. Modulation of TSC-mTOR signaling on immune cells in immunity and autoimmunity.
Yang H; Wang X; Zhang Y; Liu H; Liao J; Shao K; Chu Y; Liu G
J Cell Physiol; 2014 Jan; 229(1):17-26. PubMed ID: 23804073
[TBL] [Abstract][Full Text] [Related]
20. mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia.
Nguyen LH; Brewster AL; Clark ME; Regnier-Golanov A; Sunnen CN; Patil VV; D'Arcangelo G; Anderson AE
Epilepsia; 2015 Apr; 56(4):636-46. PubMed ID: 25752454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
